More Detailed Information on Key Tier 1 Applications - Hereditary Breast and Ovarian Cancer (HBOC)
Clinically significant mutations in the BRCA1 and BRCA2 genes are associated with an increased risk of breast, ovarian, tubal, peritoneal, and other cancers. BRCA testing looks for these variations, which can help patients and health care providers understand a person’s risk for these cancers. For women who have a BRCA mutation, the risk of developing breast or ovarian cancer is greatly increased, with current cumulative risk estimates ranging from 45 - 65% for breast cancer and 10 - 39% for ovarian cancer by age 70. [PDF 195.88 KB] Men with BRCA mutations, especially BRCA2 mutations, are also at increased risk for breast cancer. Certain other cancers may be more frequently seen in mutation carriers of either sex.
Facts about BRCA1 and BRCA2
- BRCA mutations account for 3% of breast cancer and 10% of ovarian cancer cases in the U.S. each year [PDF 3.83 MB]
- Genetic tests are available to check for BRCA1 and BRCA2 mutations. Genetic counseling is recommended before and after the tests, to make sure that the risks and benefits are understood, that informed consent is achieved, and that the appropriate test is being ordered.
- If a harmful BRCA1 or BRCA2 mutation is found, several options are available to help reduce cancer risk.
- Many research studies are being conducted to find newer and better ways of detecting, treating, and preventing cancer in BRCA1 and BRCA2 mutation carriers.
In 2013, the U.S. Preventive Services Task Force (USPSTF) updated and reaffirmed its 2005 recommendations for BRCA testing stating: “The USPSTF recommends that primary care providers screen women who have family members with breast, ovarian, tubal, or peritoneal cancer with 1 of several screening tools designed to identify a family health history that may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes (BRCA1 or BRCA2). Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing. (B recommendation)”
The USPSTF is an independent panel of non-Federal experts in prevention and evidence-based medicine. The USPSTF conducts scientific evidence reviews of a broad range of clinical preventive health care services and develops recommendations for primary care clinicians and health systems.
The USPSTF guidelines focus on family health history in unaffected individuals in the general population. The Tier 1 application, which follows the USPSTF guidelines, therefore focuses on this public health approach as well.
The Task Force concluded that BRCA testing may not be right for everyone. They “recommend against routine genetic counseling or BRCA testing for women whose family health history is not associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes. (D recommendation).”
Women might be at increased risk of having BRCA mutations if their family health history includes one or more of the following in their first- or second-degree relatives (maternal and paternal sides of the family are equally important):
- Multiple relatives with either breast or ovarian cancer;
- Breast cancer at a young age (under 50 years);
- Presence of breast and ovarian cancer among relatives;
- A relative with primary cancers of both breasts;
- One or more family members with two primary types of BRCA-related cancer;
- Presence of breast cancer in one or more male relatives;
- Ashkenazi Jewish ancestry;
- A relative with a known BRCA mutation.
The USPSTF recommendation notes that “several familial risk stratification tools are available to determine the need for in-depth genetic counseling, such as the Ontario Family Health History Assessment Tool, Manchester Scoring System, Referral Screening Tool, Pedigree Assessment Tool, and FHS-7 [PDF 195.88 KB].”
Genetic counseling and appropriate genetic testing for BRCA1 and BRCA2 based on the USPSTF guidelines, followed by appropriate management, are expected to reduce morbidity and mortality due to breast and ovarian cancer.
For women with BRCA mutations, interventions that might reduce the risk of cancer include “earlier, more frequent, or intensive cancer screening; risk-reducing medications (i.e., tamoxifen or raloxifene); and risk-reducing surgery (e.g., mastectomy or salpingo-oophorectomy) [PDF 195.88 KB]”; however, the USPSTF found that the strength of evidence varies across the types of interventions. In studies cited in the USPSTF recommendation, prophylactic bilateral mastectomy reduced breast cancer risk by 85% or more, and prophylactic oophorectomy reduced ovarian cancer risk by 85% or more and breast cancer risk by 53% or more. The USPSTF found the evidence lacking regarding the effect of intensive screening on clinical outcomes in women who are BRCA mutation carriers. The USPSTF cited randomized controlled trials finding that the medications tamoxifen and raloxifene reduced the incidence of invasive breast cancer, but also noted that clinical trials of these medications have not been conducted specifically in women who are BRCA mutation carriers.
The prevalence of BRCA mutations in the general population is estimated at 1/300 -1/500. [PDF 195.88 KB] 2010 National Health Interview Survey data, used to monitor the HP 2020 objective, reveal that approximately 47% of women with relevant family histories have not had genetic counseling for HBOC. It is not known to what degree this is due to their providers not alerting them to their increased risk status and offering them genetic counseling and/or testing. Extrapolating from the National Health Interview Survey one can assume that in the United States a very large number of women with relevant family histories who might benefit from genetic counseling and possible genetic testing for HBOC have not utilized these services. Genetic counseling and evaluation for BRCA genetic testing based on the USPSTF recommendation is a preventive service now covered under the Affordable Care Act (ACA). Both genetic counseling and testing, if appropriate, are included in the ACA-covered preventive service for women whose family histories are consistent with USPSTF guidelines.
Note: Some but not all health insurers cover genetic counseling and testing for BRCA1 and BRCA2 when recommended by a provider. Some financial assistance may be available through testing providers or advocacy organizations.
Public health interventions for Tier 1 BRCA applications involve public health departments working with and providing information to medical providers and payers that facilitate actions to identify individuals and families at risk so that their health care system can screen and/or provide medical service options to them early, before the harms and expense of disease progression can occur. Based on accomplishments in Michigan, Oregon, Georgia and other states, public health departments can now consider successful examples of public health interventions described below under “Phase 1 Approaches” for HBOC including: 1) enhancing cancer registry reporting including “bi-directional” reporting in partner provider systems for potential BRCA related hereditary cancers; 2) informing evidence-based policy making such as expansion of coverage for services specified by Tier 1 recommendations by partner payers; 3) developing and tracking surveillance indicators to follow the progress of achieving widespread implementation of Tier 1 recommendations including the BRCA Healthy People 2020 objective; and 4) instituting educational outreach programs targeting the public and health professional groups with an interest in or need to know about Tier 1 BRCA recommendations. These efforts, called “Phase 1” approaches, focus on “low hanging fruit”; currently few states have implemented such activities. However, some states may be ready for advanced “Phase 2” projects such as cascade screening. While the challenges and opportunities within each state differ, success in any of these efforts requires the establishment of strong partnerships between public health and providers, payers, and/or cancer registries within each state’s boundaries.
Note: The current examples of state efforts to implement Tier 1 BRCA recommendations are based on the 2005 USPSTF BRCA recommendation. Applying these examples going forward could require modifications to reflect the newly released 2013 update to the USPSTF BRCA recommendation.
A word about high-risk populations:
Ashkenazi (Eastern European) Jews are at significantly increased risk for three specific mutations that are associated with HBOC; more than 2% of individuals from this ethnic background carry one of these mutations. Individuals whose ancestors are from Norway, Holland and Iceland have a somewhat higher rate of mutations that are associated with HBOC. Also, there is evidence that African American women receive appropriate genetic counseling and testing as per the USPSTF recommendation at a much lower rate than other groups. These are important health disparity issues. Public health departments might consider this information when developing programs.